Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation
Advanced Science · 2025
DOI: 10.1002/advs.202501149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Zixian Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China. Hauptthemen laut MEDLINE: Cisplatin, Epithelial-Mesenchymal Transition, Mouth Neoplasms, Phosphate-Binding Proteins. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Guangdong, Guangzhou Science and Technology Project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Neoadjuvant chemotherapy has been widely used for the treatment of solid tumors. However, clinical observations have shown that patients with oral squamous cell carcinoma (OSCC) who are receiving neoadjuvant chemotherapy with cisplatin still face issues such as a poor lymph node response and even lymph node progression, but the underlying mechanisms remain unidentified. In this work, it is found that low‐dose cisplatin promoted oral squamous cell carcinoma migration, invasion and lymph node metastasis, and gasdermin D (GSDMD) is identified as a potential regulator. GSDMD interacted with MMP14, promoting its expression and epithelial‒mesenchymal transition (EMT) activation without activating pyroptosis. Moreover, pH‐responsive nanoparticles (NPs) for the systemic delivery of a GSDMD siRNA (siGSDMD) is developed and showed that this NP‐delivered siGSDMD can effectively inhibit OSCC tumor growth and metastasis via the efficient silencing of GSDMD expression in vivo. This findings indicate that GSDMD can be a biomarker to predict the prognosis of OSCC patients receiving neoadjuvant chemotherapy and that NP‐mediated GSDMD silencing can be a promising strategy for the treatment of patients with advanced OSCC receiving neoadjuvant chemotherapy with cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
- Nanhai Translational Innovation Center of Precision Immunology, Sun Yat-Sen Memorial Hospital, Foshan, 528200, China.
- Hospital of stomatology, the First Affiliated Hospital of Jinan University, School of Stomatology, Jinan University, Guangzhou, 510632, China.
ORCID-Profile: Zixian Huang, Zhiquan Huang
Förderung
- National Natural Science Foundation of China
- Science and Technology Program of Guangdong
- Guangzhou Science and Technology Project
Zitieren
APA
Huang, Z., Jiang, Q., Zhang, Q., Lu, N., Rui, X., Chen, R., Wang, Y., Wang, Y., Xu, X., & Huang, Z. (2025). Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation. Advanced Science. https://doi.org/10.1002/advs.202501149
Vancouver
Huang Z, Jiang Q, Zhang Q, Lu N, Rui X, Chen R, et al. Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation. Advanced Science. 2025. doi:10.1002/advs.202501149
BibTeX
@article{Huang2025,
author = {Huang, Zixian and Jiang, Qiming and Zhang, Qianyu and Lu, Nan and Rui, Xi and Chen, Rui and Wang, Yan and Wang, Yuepeng and Xu, Xiaoding and Huang, Zhiquan},
title = {Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202501149}
}
EUVIMED